Product Description
BMS-986397 is being developed by Bristol-Myer Squibb for the treatment of Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04951778?term=BMS-986397&draw=2&rank=1)
Mechanisms of Action: CK1a Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Bristol-Myers Squibb presented P1 Acute Myeloid Leukemia results on 2024-12-09 for BMS-986397
Highest Development Phases
Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04951778 |
CC-91633-AML-001 | P1 |
Terminated |
Acute Myeloid Leukemia|Myelodysplastic Syndrome |
2025-07-30 |
50% |
2025-08-29 |